Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: Data from the INC-EU Prospective Observational European Neutropenia Study

British Journal of Haematology

Volumn 144, Issue 5, 2009, Pages 677-685

  Pettengell, Ruth ^a   Bosly, André ^b   Szucs, Thomas D ^c   Jackisch, Christian ^d   Leonard, Robert ^e   Paridaens, Robert ^f   Constenla, Manuel ^g   Schwenkglenks, Matthias ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Klinikum Offenbach   (Germany)

^e CHARING CROSS HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g Servicio de Oncologia   (Spain)

Author keywords

Chemotherapy; Neutropenia; Non Hodgkin lymphoma; Risk factors

Indexed keywords

ALBUMIN; BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BODY WEIGHT; COLONY-STIMULATING FACTORS, RECOMBINANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EUROPE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; PREDNISONE; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; VINCRISTINE; YOUNG ADULT;

EID: 58849139235     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07514.x     Document Type: Article

References (37)

1. Aapro, M.S., Cameron, D.A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., Kearney, N., Lyman, G.H., Tjan-Heijnen, V.C., Walewski, J., Weber, D.C. Zielinski, C. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer, 42, 2433 2453.
2. Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M. Brambilla, C. (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. New England Journal of Medicine, 332, 901 906.
3. Bosly, A., Bron, D., Van, H.A., De, B.R., Berneman, Z., Ferrant, A., Kaufman, L., Dauwe, M. Verhoef, G. (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Annals of Hematology, 87, 277 283.
4. Budman, D.R., Berry, D.A., Cirrincione, C.T., Henderson, I.C., Wood, W.C., Weiss, R.B., Ferree, C.R., Muss, H.B., Green, M.R., Norton, L. Frei, III., E. (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. Journal of the National Cancer Institute, 90, 1205 1211.
5. Casas, A.M., Rifä, J., Gonzalez Larriba, J.L., Carrato, A. Lopez Pousa, A. (2006) Risk assessment model for haematologic toxicity (HT) in patients with solid tumours (ST) during the first chemotherapy (CT) cycle. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part 1, 24 (Suppl. 18S Abstract 18516.
6. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F. Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235 242.
7. Crawford, J., Dale, D.C. Lyman, G.H. (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer, 100, 228 237.
8. Dale, D.C., McCarter, G.C., Crawford, J. Lyman, G.H. (2003) Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. Journal of the National Comprehensive Cancer Network, 1, 440 454.
9. Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, Jr., C.A. Miller, T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002 1006.
10. Goutte, C. (1997) Note on free lunches and cross-validation. Neural Computation, 9, 1245 1249.
11. Greenland, S. Finkle, W.D. (1995) A critical look at methods for handling missing covariates in epidemiologic regression analyses. American Journal of Epidemiology, 142, 1255 1264.
12. Intragumtornchai, T., Sutheesophon, J., Sutcharitchan, P. Swasdikul, D. (2000) A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leukemia & Lymphoma, 37, 351 360.
13. Klastersky, J. Paesmans, M. (2007) Risk-adapted strategy for the management of febrile neutropenia in cancer patients. Supportive Care in Cancer, 15, 477 482.
14. Komrokji, R.S. Lyman, G.H. (2004) The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opinion on Biological Therapy, 4, 1897 1910.
15. Kwak, L.W., Halpern, J., Olshen, R.A. Horning, S.J. (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. Journal of Clinical Oncology, 8, 963 977.
16. Lepage, E., Gisselbrecht, C., Haioun, C., Sebban, C., Tilly, H., Bosly, A., Morel, P., Herbrecht, R., Reyes, F. Coiffier, B. (1993) Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. Annals of Oncology, 4, 651 656.
17. Lyman, G.H. Delgado, D.J. (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer, 98, 2402 2409.
18. Lyman, G.H., Morrison, V.A., Dale, D.C., Crawford, J., Delgado, D.J. Fridman, M. (2003) Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leukemia & Lymphoma, 44, 2069 2076.
19. Lyman, G.H., Lyman, C.H. Agboola, O. (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist, 10, 427 437.
20. Lyman, G.H., Kuderer, N.M., Crawford, J., Wolff, D.A., Culakova, E., Poniewierksi, M.S. Dale, D.C. (2006) Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy. Journal of Clinical Oncology, 24, Abstract 8561.
21. Morrison, V.A., Picozzi, V., Scott, S., Pohlman, B., Dickman, E., Lee, M., Lawless, G., Kerr, R., Caggiano, V., Delgado, D., Fridman, M., Ford, J. Carter, W.B. (2001) The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clinical Lymphoma, 2, 47 56.
22. National Comprehensive Cancer Network Inc 2008a) NCCN Clinical Practice Guidelines in Oncology - Non-Hodgkin's Lymphomas V.3.2008 : http://www.nccn.org/ professionals/physician-gls/PDF/nhl.pdf.
23. National Comprehensive Cancer Network Inc 2008b) NCCN Clinical Practice Guidelines in Oncology- Prevention and Treatment of Cancer-Related Infections V.1.2008 : http://www.nccn.org/professionals/physician-gls/PDF/infections.pdf
24. Nijhuis, C.O., Kamps, W.A., Daenen, S.M., Gietema, J.A., van der Graaf, W.T., Groen, H.J., Vellenga, E., Ten Vergert, E.M., Vermeulen, K.M., de Vries-Hospers, H.G. de Bont, E.S. (2005) Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. Journal of Clinical Oncology, 23, 7437 7444.
25. Osby, E., Hagberg, H., Kvaloy, S., Teerenhovi, L., Anderson, H., Cavallin-Stahl, E., Holte, H., Myhre, J., Pertovaara, H. Bjorkholm, M. (2003) CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood, 101, 3840 3848.
26. Pettengell, R., Schwenkglenks, M. Bosly, A. (2008a) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Annals of Hematology, 87, 429 430.
27. Pettengell, R., Schwenkglenks, M., Leonard, R., Bosly, A., Paridaens, R., Constenla, M., Szucs, T.D. Jackisch, C. (2008b) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Supportive Care in Cancer, 16, 1299 1309.
28. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, 7, 379 391.
29. Rabinowitz, A.P., Weiner, N.J., Tronic, B.S., Fridman, M., Liberman, R.F. Delgado, D.J. (2006) Severe neutropenia in CHOP occurs most frequently in cycle 1: a predictive model. Leukemia & Lymphoma, 47, 853 858.
30. Repetto, L., Biganzoli, L., Koehne, C.H., Luebbe, A.S., Soubeyran, P., Tjan-Heijnen, V.C. Aapro, M.S. (2003) EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. European Journal of Cancer, 39, 2264 2272.
31. Schwenkglenks, M., Jackisch, C., Constenla, M., Kerger, J.N., Paridaens, R., Auerbach, L., Bosly, A., Pettengell, R., Szucs, T.D. Leonard, R. (2006) Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Supportive Care in Cancer, 14, 901 909.
32. Shayne, M., Culakova, E., Dale, D.C., Poniewierksi, M.S., Wolff, D.A., Crawford, J. Lyman, G. (2007a) A validated risk model for early neutropenic events in older cancer patients receiving systemic chemotherapy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part 1, 25 (Suppl. 18S Abstract 9036.
33. Shayne, M., Culakova, E., Poniewierksi, M.S., Wolff, D.A., Dale, D.C., Crawford, J. Lyman, G.H. (2007b) Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer, 110, 1611 1620.
34. Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., Balducci, L., Bennett, C.L., Cantor, S.B., Crawford, J., Cross, S.J., Demetri, G., Desch, C.E., Pizzo, P.A., Schiffer, C.A., Schwartzberg, L., Somerfield, M.R., Somlo, G., Wade, J.C., Wade, J.L., Winn, R.J., Wozniak, A.J. Wolff, A.C. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology, 24, 3187 3205.
35. Teegala, S.R., Zhou, X., Huen, A., Ji, Y., Fayad, L.E., Romaguera, J.E. Vadhan-Raj, S. (2007) Risks factors for neutropenic fever in lymphoma patients receiving chemotherapy. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part 1, 25 (Suppl. 18S Abstract 19616.
36. Vach, W. Blettner, M. (1991) Biased estimation of the odds ratio in case-control studies due to the use of ad hoc methods of correcting for missing values for confounding variables. American Journal of Epidemiology, 134, 895 907.
37. Voog, E., Bienvenu, J., Warzocha, K., Moullet, I., Dumontet, C., Thieblemont, C., Monneret, G., Gutowski, M.C., Coiffier, B. Salles, G. (2000) Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. Journal of Clinical Oncology, 18, 325 331.